Delving into the Latest Updates on Astellas Pharma Tech Co., Ltd. with Synapse

概览

关联

1

项与 Astellas Pharma Tech Co., Ltd. 相关的药物

Fezolinetant

非唑奈坦

靶点

NK3

作用机制

NK3拮抗剂

在研机构

Astellas Pharma Global Development, Inc. [+4]

原研机构

Ogeda SA [+1]

在研适应症

潮热 [+2]

非在研适应症

肝损伤

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2023-05-12

2

项与 Astellas Pharma Tech Co., Ltd. 相关的临床试验

CTR20200188 / CompletedN/A

一项在健康中国女性受试者中评估Fezolinetant的药代动力学和安全性的开放、单次给药及多次给药研究

评价健康中国女性受试者中单次和多次给药后Fezolinetant的药代动力学和安全性。

开始日期2021-03-24

申办/合作机构

Astellas Pharma Global Development, Inc.

[+3]

CTR20190934 / CompletedN/A

在中国健康受试者中评价ASP015K的药代动力学和安全性的开放性、单次和多次给药研究

在中国健康受试者中评价ASP015K 50mg、100mg和150mg单次和多次给药后的药代动力学和安全性。

开始日期2019-12-05

申办/合作机构

Astellas Pharma Tech Co., Ltd.

[+2]

100 项与 Astellas Pharma Tech Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Astellas Pharma Tech Co., Ltd. 相关的专利（医药）

登录后查看更多信息

8

项与 Astellas Pharma Tech Co., Ltd. 相关的文献（医药）

2017-07-03·Bioscience, Biotechnology, and Biochemistry4区 · 工程技术

Strain improvement of Lentzea sp. 7887 for higher yield per unit volume on hydroxylation of cyclosporine derivative FR901459

4区 · 工程技术

Article

作者: Yabutani, Tetsuya ; Ohira, Shunsuke ; Shimizu, Shiho ; Nakano, Hideo ; Tsujimoto, Mami

AbstractA Gram-positive bacterium Lentzea sp. 7887 hydroxylates a cyclosporine derivative FR901459 into AS1837812 (9-hydroxide), which is an important intermediate of candidate drugs that target the hepatitis C virus. We screened a UV-induced mutant, named M-1, which showed about 1.2-fold higher conversion yields, 2-fold higher substrate concentrations (3.69 mM), and 2.5-fold higher yield per unit volume than the wild-type strain.

2016-01-01·Cell Structure and Function4区 · 生物学

Significance of Extracellular Vesicles: Pathobiological Roles in Disease

4区 · 生物学

ReviewOA

作者: Azuma, Erika ; Hamashima, Takeru ; Ishii, Yoko ; Muramatsu, Masashi ; Sasahara, Masakiyo ; Yamamoto, Seiji

Over the past decade, many studies have been conducted on extracellular vesicles (EVs) in the fields of basic and clinical research. EVs are small sized membranous vesicles generated from many type of cells upon activation by environmental stresses such as heat, hypoxia, and irradiation. EVs theoretically consist of microparticles/microvesicles, exosomes, and apoptotic bodies by different productive mechanisms. Clinically, EVs are observed in the blood stream of patients suffering from acute and chronic inflammation evoked by various diseases, and number of EVs in blood flow is often dependent on the inflammatory status and severity of the diseases. To date, it has been reported that small molecules such as RNAs and proteins are encapsulated in EVs; however, the functions of EVs are still unclear in the biological, pathological, and clinical aspects. In this review, we summarize and discuss the biogenesis-based classification, expected function, and pathobiological activities of EVs.

2015-01-01·CHEMICAL & PHARMACEUTICAL BULLETIN4区 · 医学

Characterization and Thermodynamic Stability of Polymorphs of Di(arylamino) Aryl Compound ASP3026

4区 · 医学

Article

作者: Takeguchi, Kazuhiro ; Okada, Minoru ; Yamazaki, Kouji ; Ieda, Shigeru ; Takiyama, Hiroshi ; Hirakura, Yutaka ; Shimada, Itsuro

ASP3026 (N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine) was developed in Astellas Pharma Inc. as a novel and selective inhibitor of the fusion protein EML4-ALK. We investigated the thermodynamic stability of five polymorphs of ASP3026 (A01, A02, A03, A04, and A05) in detail. To determine the most stable form at ambient temperature, powder X-ray diffraction, differential scanning calorimetry, and solubility measurements were conducted. Of the five polymorphs, A04 was the most stable and A05 was the least stable. The relationship between A04 and A03 and A04 and A01 were mutually monotropic, while that between A01 and A02 was enantiotropic. The transition temperature from A02 to A01 was estimated as 325 K. A02 was more thermodynamically stable at ambient temperature than A01. Furthermore, the method to estimate polymorphic transition temperatures using solution calorimetry was found to be effective. The systematic characterization of ASP3026 polymorphs presented in this study enables the selective crystallization of the most stable form and design of solid formulations.

100 项与 Astellas Pharma Tech Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Astellas Pharma Tech Co., Ltd. 相关的转化医学

登录后查看更多信息